165 related articles for article (PubMed ID: 19554030)
1. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma.
Gasperini P; Tosato G
Leukemia; 2009 Oct; 23(10):1867-74. PubMed ID: 19554030
[TBL] [Abstract][Full Text] [Related]
2. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.
Goto H; Kudo E; Kariya R; Taura M; Katano H; Okada S
J Cancer Res Clin Oncol; 2015 Mar; 141(3):465-74. PubMed ID: 25304617
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Bhatt AP; Bhende PM; Sin SH; Roy D; Dittmer DP; Damania B
Blood; 2010 Jun; 115(22):4455-63. PubMed ID: 20299510
[TBL] [Abstract][Full Text] [Related]
5. Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
Mediani L; Gibellini F; Bertacchini J; Frasson C; Bosco R; Accordi B; Basso G; Bonora M; Calabrò ML; Mattiolo A; Sgarbi G; Baracca A; Pinton P; Riva G; Rampazzo E; Petrizza L; Prodi L; Milani D; Luppi M; Potenza L; De Pol A; Cocco L; Capitani S; Marmiroli S
Oncotarget; 2016 Feb; 7(5):5521-37. PubMed ID: 26575168
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
7. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.
Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S
Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981
[TBL] [Abstract][Full Text] [Related]
8. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
[TBL] [Abstract][Full Text] [Related]
9. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
Boulanger E; Afonso PV; Yahiaoui Y; Adle-Biassette H; Gabarre J; Agbalika F
Am J Transplant; 2008 Mar; 8(3):707-10. PubMed ID: 18261181
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway.
Goto H; Kariya R; Shimamoto M; Kudo E; Taura M; Katano H; Okada S
Cancer Sci; 2012 Apr; 103(4):775-81. PubMed ID: 22320346
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma.
Calabrò ML; Gasperini P; Di Gangi IM; Indraccolo S; Barbierato M; Amadori A; Chieco-Bianchi L
Blood; 2009 May; 113(19):4525-33. PubMed ID: 19196659
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.
Sin SH; Roy D; Wang L; Staudt MR; Fakhari FD; Patel DD; Henry D; Harrington WJ; Damania BA; Dittmer DP
Blood; 2007 Mar; 109(5):2165-73. PubMed ID: 17082322
[TBL] [Abstract][Full Text] [Related]
15. A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma.
Goto H; Kariya R; Matsuda K; Kudo E; Katano H; Okada S
Leuk Res; 2016 Mar; 42():37-42. PubMed ID: 26859781
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Dai L; Lin Z; Qiao J; Chen Y; Flemington EK; Qin Z
Oncogene; 2017 Aug; 36(35):5068-5074. PubMed ID: 28459467
[TBL] [Abstract][Full Text] [Related]
17. Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo.
Towata T; Komizu Y; Suzu S; Matsumoto Y; Ueoka R; Okada S
Leuk Res; 2010 Jul; 34(7):906-11. PubMed ID: 20074798
[TBL] [Abstract][Full Text] [Related]
18. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.
Huye LE; Nakazawa Y; Patel MP; Yvon E; Sun J; Savoldo B; Wilson MH; Dotti G; Rooney CM
Mol Ther; 2011 Dec; 19(12):2239-48. PubMed ID: 21878902
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a novel VEGF-producing HHV-8-unrelated PEL-like lymphoma cell line, OGU1.
Kawauchi K; Ogasawara T; Aiba M; Fujibayashi M; Sanaka T; Sakura H; Shibuya M
Eur J Haematol; 2016 Feb; 96(2):144-51. PubMed ID: 25846106
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
